# TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

> **NCT04197687** · PHASE2 · UNKNOWN · sponsor: **Academic and Community Cancer Research United** · enrollment: 480 (estimated)

## Conditions studied

- Breast Adenocarcinoma
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Multi-epitope HER2 Peptide Vaccine TPIV100
- **BIOLOGICAL:** Pertuzumab
- **OTHER:** Placebo Administration
- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** Trastuzumab
- **BIOLOGICAL:** Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT04197687
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-20
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2023-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04197687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04197687, "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04197687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*